Role of Akt Activation in PARP Inhibitor Resistance in Cancer
Open Access
- 25 February 2020
- Vol. 12 (3), 532
- https://doi.org/10.3390/cancers12030532
Abstract
Poly(ADP-ribose) polymerase (PARP) inhibitors have recently been introduced in the therapy of several types of cancers not responding to conventional treatments. However, de novo and acquired PARP inhibitor resistance is a significant limiting factor in the clinical therapy, and the underlying mechanisms are not fully understood. Activity of the cytoprotective phosphatidylinositol-3 kinase (PI3K)-Akt pathway is often increased in human cancer that could result from mutation, expressional change, or amplification of upstream growth-related factor signaling elements or elements of the Akt pathway itself. However, PARP-inhibitor-induced activation of the cytoprotective PI3K-Akt pathway is overlooked, although it likely contributes to the development of PARP inhibitor resistance. Here, we briefly summarize the biological role of the PI3K-Akt pathway. Next, we overview the significance of the PARP-Akt interplay in shock, inflammation, cardiac and cerebral reperfusion, and cancer. We also discuss a recently discovered molecular mechanism that explains how PARP inhibition induces Akt activation and may account for apoptosis resistance and mitochondrial protection in oxidative stress and in cancer.This publication has 147 references indexed in Scilit:
- On PAR with PARP: cellular stress signaling through poly(ADP-ribose) and PARP-1Genes & Development, 2012
- Autophosphorylation and ATM ActivationOnline Journal of Public Health Informatics, 2011
- Inhibiting poly(ADP-ribose) polymerase: a potential therapy against oligodendrocyte deathBrain, 2010
- Evidence that Inositol Polyphosphate 4-Phosphatase Type II Is a Tumor Suppressor that Inhibits PI3K SignalingCancer Cell, 2009
- Glycogen Synthase Kinase-3 and Cancer: Good Cop, Bad Cop?Cancer Cell, 2008
- An Integrative Genomic and Proteomic Analysis of PIK3CA, PTEN, and AKT Mutations in Breast CancerCancer Research, 2008
- Glycogen synthase kinase 3 (GSK3) in the heart: a point of integration in hypertrophic signalling and a therapeutic target? A critical analysisBritish Journal of Pharmacology, 2008
- Survival kinases in ischemic preconditioning and postconditioningCardiovascular Research, 2006
- The PARP superfamilyBioEssays, 2004
- Targeting RAS signalling pathways in cancer therapyNature Reviews Cancer, 2003